As all subjects in our study were patients with prostate cancer on ADT, it was not possible to distinguish whether this correlation between CRT activation and TSPO uptake is a feature specific to ADT treatment or to prostate cancer. This evidence concerns the gene TSPO and prostate carcinoma.